Axiom Bio
Founded 2024 · 25 employees on LinkedIn · 6 known investors
Axi.om uses agentic intelligence and AI to predict, explain, and fix drug toxicity early in development by leveraging the largest experimental-to-clinical dataset of profiled molecules linked to human clinical outcomes.
Investors · 6
Abstract VenturesSan Francisco · $250K – $750K
Amplify PartnersMenlo Park · $500K – $5M
CRV (Charles River Ventures)Bay Area · $250K – $5M
Inception Studio CapitalSilicon Valley · $100K – $1.5M
Atria VenturesreportedSan Francisco · $500K – $3Mvia Chris Leiter · inferred
Dimension CapitalreportedSan Francisco · $1M – $10M
Competitors · 3
by search overlap
Numerion Labs13 shared keywordsNumerion combines drug discovery expertise with machine learning and computational chemistry. The company applies AI to drug development.
Axiom Therapeutics12 shared keywordsAxiom Therapeutics runs a drug discovery platform for covalent inhibitors, applying machine learning to speed up physics-based simulations. The work is aimed at oncology research teams pursuing targets that have been difficult to drug.
Axiom9 shared keywordsAxiom provides a fully managed, petabyte-scale, schema-less event store for observability data, letting engineering teams ingest and retain logs, traces, metrics, and events with high compression and usage-based pricing. It offers query languages (APL and MPL) modeled on the Splunk experience, a native MCP server for AI agents, and tools to migrate from or run alongside Splunk.
Companies competing with Axiom Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Top 8 Proprietary Trading Firms & Best Forex Prop Firms / Axiaxi.com · Jul 2026Frequently asked questions
- What does Axiom Bio do?
- Axi.om uses agentic intelligence and AI to predict, explain, and fix drug toxicity early in development by leveraging the largest experimental-to-clinical dataset of profiled molecules linked to human clinical outcomes.
- Who are Axiom Bio's investors?
- Axiom Bio's investors include Abstract Ventures, Amplify Partners, CRV (Charles River Ventures), Inception Studio Capital, Atria Ventures, Dimension Capital.